Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
interferon beta-1b
Novartis Europharm Limited
L03AB08
interferon beta-1b
Immunostimulants,
Multiple Sclerosis
Extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
Revision: 25
Authorised
2008-05-20
33 B. PACKAGE LEAFLET 34 PACKAGE LEAFLET: INFORMATION FOR THE USER EXTAVIA 250 MICROGRAM/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION interferon beta-1b READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Extavia is and what it is used for 2. What you need to know before you use Extavia 3. How to use Extavia 4. Possible side effects 5. How to store Extavia 6. Contents of the pack and other information Annex – self-injection procedure 1. WHAT EXTAVIA IS AND WHAT IT IS USED FOR WHAT EXTAVIA IS Extavia is a type of medicine known as interferon used to treat multiple sclerosis. Interferons are proteins produced by the body that help it fight against attacks on the immune system such as viral infections. HOW EXTAVIA WORKS MULTIPLE SCLEROSIS (MS) is a long-term condition that affects the central nervous system (CNS), particularly the functioning of the brain and spinal cord. In MS, inflammation destroys the protective sheath (called myelin) around the nerves of the CNS and stops the nerves from working properly. This is called demyelination. The exact cause of MS is unknown. An abnormal response by the body’s immune system is thought to play an important part in the process which damages the CNS. THE DAMAGE TO THE CNS can occur within an MS attack (relapse). It can cause temporary disability, such as difficulty walking. Symptoms may disappear completely or partly. Interferon beta-1b has been shown to change the response of the immune system and to help to reduce disease activity. HOW Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Extavia 250 microgram/ml powder and solvent for solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Extavia contains 300 microgram (9.6 million IU) of recombinant interferon beta-1b per vial*. After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta- 1b. * produced by genetic engineering from strain of _Escherichia coli_ . For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. Powder - white to off-white in colour. Solvent - clear/colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Extavia is indicated for the treatment of: • Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1). • Patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years. • Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The treatment with Extavia should be initiated under the supervision of a physician experienced in the treatment of the disease. Posology _Adults and adolescents from 12-17 years of age _ The recommended dose of Extavia is 250 microgram (8.0 million IU), contained in 1 ml of the reconstituted solution (see section 6.6), to be injected subcutaneously every other day. Generally, dose titration is recommended at the start of treatment. Patients should be started at 62.5 microgram (0.25 ml) subcutaneously every other day, and increased slowly to a dose of 250 microgram (1.0 ml) every other day (see Table A). The titration period may be adjusted, if any significant adverse reaction occurs. In order to obtain Przeczytaj cały dokument